The estimated Net Worth of Stephane Peluso is at least $579 millier dollars as of 2 August 2022. Dr Peluso owns over 50,000 units of Infinity Pharmaceuticals stock worth over $1,041 and over the last 3 years he sold INFI stock worth over $0. In addition, he makes $577,633 as Chief Scientific Officer at Infinity Pharmaceuticals.
Sign up
Dr D INFI stock SEC Form 4 insiders trading
Dr has made over 1 trades of the Infinity Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of INFI stock worth $1,000 on 2 August 2022.
The largest trade he's ever made was exercising 50,000 units of Infinity Pharmaceuticals stock on 2 August 2022 worth over $1,000. On average, Dr trades about 16,667 units every 0 days since 2021. As of 2 August 2022 he still owns at least 52,046 units of Infinity Pharmaceuticals stock.
You can see the complete history of Dr Peluso stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Stephane Peluso Ph.D. biography
Dr. Stephane Peluso Ph.D. is the Chief Scientific Officer at Infinity Pharmaceuticals.
What is the salary of Dr D?
As the Chief Scientific Officer of Infinity Pharmaceuticals, the total compensation of Dr D at Infinity Pharmaceuticals is $577,633. There are 7 executives at Infinity Pharmaceuticals getting paid more, with Adelene Perkins having the highest compensation of $1,680,860.
How old is Dr D?
Dr D is 51, he's been the Chief Scientific Officer of Infinity Pharmaceuticals since . There are 13 older and 4 younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.
What's Dr D's mailing address?
Stephane's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4, CAMBRIDGE, MA, 02138.
Insiders trading at Infinity Pharmaceuticals
Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.
What does Infinity Pharmaceuticals do?
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
What does Infinity Pharmaceuticals's logo look like?
Complete history of Dr Peluso stock trades at Infinity Pharmaceuticals
Infinity Pharmaceuticals executives and stock owners
Infinity Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Adelene Perkins,
Chairman of the Board, Chief Executive Officer -
Samuel Agresta,
Director -
Lawrence Bloch,
President, Treasurer -
Adelene Q. Perkins,
Chairman & CEO -
Seth Tasker,
Senior Vice President, Chief Business Officer and Secretary -
Dr. Lawrence E. Bloch,
Pres & Treasurer -
Dr. Robert Ilaria Jr., M.D.,
Chief Medical Officer -
Dr. Stephane Peluso Ph.D.,
Chief Scientific Officer -
Seth A. Tasker,
Sr. VP, Chief Bus. Officer & Sec. -
Michael Venuti,
Independent Director -
Richard Gaynor,
Independent Director -
Anthony Evnin,
Independent Director -
David Beier,
Independent Director -
Norman Selby,
Lead Independent Director -
Seth A. Tasker J.D.,
Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. -
Dr. Jeffery L. Kutok M.D., Ph.D.,
Chairman of Scientific Advisory Board -
Dr. Lawrence E. Bloch J.D., M.D.,
Pres & Treasurer -
Jayne Kauffman,
Sr. Exec. Coordinator -
Rossitza Alargova Ph.D.,
Head of Pharmaceutical Devel. -
Dr. Jeffery L. Kutok,
Chairman of Scientific Advisory Board -
Melissa Hackel,
VP of Fin. -
Michael Kauffman,
Director -
Partners L P/Ilbiotechnolog...,
-
Jeffery Kutok,
Chief Scientific Officer -
Ian F Smith,
Director -
Christopher M Lindblom,
Assistant Treasurer -
Jeffrey Berkowitz,
Director -
Jose Baselga,
Director -
Eric S Lander,
Director -
Thomas J. Jr. Lynch,
Director -
Patrick Pak Tin Lee,
Director -
Medical Co L.P. Rosebay,
10% owner -
Steven H Holtzman,
CEO and Assistant Secretary -
Martin Babler,
Director -
David Roth,
Chief Medical Officer -
Winselow S. Jr. Tucker,
Vice President, Marketing -
Gwen A. Fyfe,
Director -
Joshua Hamermesh,
See Remarks -
Co Beacon,
10% owner -
Winston K.C. Lam,
General Counsel -
Gerald E Quirk,
VP,Cor. Affairs & Gnrl Counsel -
Vito J. Palombella,
Chief Scientific Officer -
Thomas Joseph Burke,
Assistant Treasurer -
Harry F Jr Hixson,
Director -
Vicki L Sato,
Director -
Jeffrey K Tong,
VP, Cor. & Product Development -
Herm Rosenman,
Director -
Arnold J Levine,
Director -
James B Tananbaum,
Director -
D Ronald Daniel,
Director -
Franklin Moss,
Director -
William C Jr Bertrand,
General Counsel -
Sujay Kango,
-
Partners L P/Ilbiotechnolog...,
-
Stephane Peluso,
Chief Scientific Officer -
Robert Jr. Ilaria,
Chief Medical Officer -
Brian Schwartz,